A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Researchers have discovered a way to help aging intestines heal themselves using CAR T-cell therapy, targeting senescent ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.